Leerink Partnrs Has Negative Forecast for GPCR Q3 Earnings

Key Points

• Leerink Partners has revised its Q3 2025 EPS estimate for Structure Therapeutics, decreasing it from ($0.28) to ($0.38) per share, indicating a more negative outlook for the company's earnings.
• Structure Therapeutics recently reported a loss of ($0.36) per share, which was below analysts' consensus estimates, suggesting challenges in meeting financial expectations.
• Despite the negative forecast and recent earnings miss, eight analysts give Structure Therapeutics a "Buy" rating with an average price target of $75.71, reflecting potential confidence in the stock's long-term growth.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Stock analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Structure Therapeutics in a research note issued on Thursday, August 7th. Leerink Partnrs analyst D. Risinger now expects that the company will earn ($0.38) per share for the quarter, down from their previous forecast of ($0.28). The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics' FY2025 earnings at $1.50 EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.87) EPS and FY2029 earnings at $0.75 EPS.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).

A number of other research analysts have also commented on GPCR. Citigroup began coverage on Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Guggenheim decreased their price target on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday. JMP Securities dropped their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a report on Thursday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Finally, HC Wainwright lowered their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research report on Thursday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics currently has an average rating of "Buy" and a consensus price target of $75.71.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $16.31 on Monday. The firm has a 50 day simple moving average of $19.78 and a 200 day simple moving average of $21.76. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $45.37. The firm has a market cap of $939.46 million, a P/E ratio of -15.53 and a beta of -1.89.

Hedge Funds Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $34,000. National Bank of Canada FI grew its holdings in Structure Therapeutics by 1,448.2% during the first quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after purchasing an additional 2,766 shares during the period. Assetmark Inc. increased its stake in Structure Therapeutics by 39.9% in the second quarter. Assetmark Inc. now owns 2,877 shares of the company's stock valued at $60,000 after purchasing an additional 820 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in Structure Therapeutics by 25.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares during the period. Finally, ANTIPODES PARTNERS Ltd boosted its position in shares of Structure Therapeutics by 310.7% during the first quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after purchasing an additional 3,213 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.